NEW YORK, Aug. 22 – Gilead Sciences is selling its 49 percent interest in oligonucleotides manufacturer Proligo to Degussa Corporation, which currently holds the remaining Proligo shares, the company announced on Wednesday.
The deal, expected to close on Aug. 31, is for $14 million in cash, according to Foster City, Calif.-based Gilead.